PPC-5650

PPC-5650 is a small molecule drug developed as a potent antagonist of acid-sensing ion channel 1a (ASIC1a). It acts by modulating the activity of acid-sensing ion channels, which are involved in pain signaling pathways. By inhibiting ASIC1a, PPC-5650 reduces pain signals under conditions where these channels are upregulated. The drug was investigated for its potential to treat pain associated with conditions such as gastroesophageal reflux disease (GERD) and irritable bowel syndrome (IBS). Clinical studies showed that PPC-5650 could reduce sensitization to mechanical stimulation in the esophagus but did not demonstrate efficacy in reducing rectal sensitivity in IBS patients. The overall safety and tolerability profile was acceptable during clinical trials[1][2][3][5][7]. Development of PPC-5650 for pain indications has been discontinued.